AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Expected to Post Earnings of -$0.44 Per Share

Analysts expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will announce earnings per share of ($0.44) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for AMAG Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.48). AMAG Pharmaceuticals posted earnings per share of ($0.60) during the same quarter last year, which would suggest a positive year over year growth rate of 26.7%. The firm is scheduled to report its next quarterly earnings report on Thursday, February 6th.

On average, analysts expect that AMAG Pharmaceuticals will report full year earnings of ($2.60) per share for the current financial year, with EPS estimates ranging from ($2.62) to ($2.55). For the next fiscal year, analysts expect that the company will report earnings of ($1.28) per share, with EPS estimates ranging from ($3.31) to ($0.55). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.19). The company had revenue of $84.13 million for the quarter, compared to the consensus estimate of $88.25 million. AMAG Pharmaceuticals had a negative return on equity of 34.59% and a negative net margin of 88.54%. The business’s revenue for the quarter was down 31.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.89 earnings per share.

AMAG has been the subject of several recent research reports. Piper Jaffray Companies downgraded AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $9.00 to $6.00 in a report on Wednesday, October 30th. Barclays restated a “buy” rating and set a $14.00 price objective (down from $16.00) on shares of AMAG Pharmaceuticals in a research note on Sunday, November 3rd. BidaskClub raised shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 23rd. Needham & Company LLC reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Friday, October 25th. Finally, ValuEngine lowered shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $13.28.

Shares of NASDAQ:AMAG opened at $10.76 on Tuesday. The stock has a market cap of $375.38 million, a price-to-earnings ratio of -2.77 and a beta of 0.35. The company has a quick ratio of 1.53, a current ratio of 1.67 and a debt-to-equity ratio of 0.58. AMAG Pharmaceuticals has a 12-month low of $6.81 and a 12-month high of $18.19. The business’s 50 day moving average is $10.52 and its 200 day moving average is $10.36.

Hedge funds have recently bought and sold shares of the business. Camber Capital Management LP grew its stake in AMAG Pharmaceuticals by 13.2% in the 2nd quarter. Camber Capital Management LP now owns 3,000,000 shares of the specialty pharmaceutical company’s stock valued at $29,970,000 after purchasing an additional 350,000 shares during the period. Rhumbline Advisers raised its stake in shares of AMAG Pharmaceuticals by 5.0% during the 3rd quarter. Rhumbline Advisers now owns 114,850 shares of the specialty pharmaceutical company’s stock worth $1,327,000 after purchasing an additional 5,457 shares during the period. Aperio Group LLC bought a new stake in shares of AMAG Pharmaceuticals during the 2nd quarter worth $78,000. Permanens Capital L.P. boosted its holdings in shares of AMAG Pharmaceuticals by 53.0% in the 3rd quarter. Permanens Capital L.P. now owns 407,811 shares of the specialty pharmaceutical company’s stock worth $4,710,000 after buying an additional 141,311 shares during the last quarter. Finally, Tyers Asset Management LLC boosted its holdings in shares of AMAG Pharmaceuticals by 32.2% in the 2nd quarter. Tyers Asset Management LLC now owns 5,840 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 1,424 shares during the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Recommended Story: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.